While it was found to be pro-tumorigenic and associated with poor prognosis in most cancer types, including glioma, lung, breast, ovarian, colorectal, gastric and prostate cancer (Li K. et al., 2019; Jin et al., 2020; Zhao et al., 2021; Liu H. et al., 2022; Li et al., 2022; Wang et al., 2023; Yue et al., 2023), some studies suggest that high expression of TROAP could predict better survival in acute myeloid leukemia (He et al., 2023). Here, TROAP is linked to prostate cancer.